Castle Biosciences ( (CSTL) ) has issued an update.
Castle Biosciences reported a strong financial performance for the year 2024, with a 51% increase in revenue to $332 million and a 36% rise in test report volume compared to 2023. The company achieved significant growth in its dermatologic and gastroenterology test reports, driven by the clinical value of its tests and strategic commercial execution. The company anticipates generating between $280-295 million in revenue in 2025, focusing on operational excellence and strategic opportunities to enhance stockholder value.
More about Castle Biosciences
Castle Biosciences is a company focused on improving health through innovative diagnostic tests that guide patient care. It operates in the healthcare industry, providing tests such as DecisionDx-Melanoma, DecisionDx-SCC, and TissueCypher Barrett’s Esophagus, with a market focus on dermatology, gastroenterology, and ophthalmology.
YTD Price Performance: -7.13%
Average Trading Volume: 384,430
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $729.3M
See more data about CSTL stock on TipRanks’ Stock Analysis page.